Cytiva is building a new 7,360 square meter facility in Grens, Switzerland, in the new Signy Park, for the manufacture of single use kits for the Sepax and Sefia cell processing systems. The facility will meet global regulatory requirements and is expected to be fully operational in 2022.
Cytiva is building a new 7,360 square meter facility in Grens, Switzerland, in the new Signy Park, for the manufacture of single use kits for the Sepax and Sefia cell processing systems. The facility will meet global regulatory requirements and is expected to be fully operational in 2022.
Nemaco, a Dutch-Swiss based developer that specializes in the realization of made-to-measure buildings for multinational corporations, will design and build the new facility. It will be customized to meet specific business needs and will be able to scale with industry growth.
In addition to its manufacturing capabilities, the new site will house a Center of Excellence that will feature advanced cell and gene therapy manufacturing facilities and will also serve as a base for European customer trainings and educational initiatives. The site will also support a growing Research & Development team and other subject matter experts.
The new facility will be able to house up to 200 employees.
Emmanuel Ligner, President & CEO, Cytiva said: “With more than 900 regenerative companies worldwide, we see increased demand for our resources and expertise. Our Swiss operations are critical to the success of our cell and gene therapy customers, so this new facility will allow us to accelerate capacity and provide a single location where our research, engineering and service teams can thrive. Plus, we will be able to attract the region’s top talent.”
Catarina Flyborg, General Manager, Cell and Gene Therapy, Cytiva, said: “From clinical trials to commercialization, regenerative medicine is going to transform global healthcare. This new facility will allow us to meet anticipated global demand while simultaneously developing the next generation of products that will accelerate the commercialization and industrialization of cell and gene therapies.”
Rembert Berg, Chairman, Nemaco Group, said: “We are honored to start with the development of Cytiva’ new manufacturing facility in Signy Park, as the first and key long-term occupier for the Park.”
The new site will complement Cytiva global network of manufacturing facilities in the US, UK, Sweden and China.
Media Contacts
Colleen Connolly
Cytiva
[email protected]
+774 245 3893
Julie Vincent
Nemaco Suisse SA
[email protected]
+41 22 362 06 11